Graham Brady is a Gastroenterology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
1st Floor Taubman Center Recp G
Ann Arbor, MI 481095334
Telephone
800-333-9013Registry record last updated 21 Jul 2022.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
49.7%Rifamycin Antibacterial25.2%Xifaxan100%Part D<11 patientsBile Acid13.6%Ursodiol100%Part D<11 patients+ 1 more class in this area
Cardiovascular
41.5%Beta blocker15.6%Carvedilol100%Part D<11 patientsAldosterone antagonist (MRA)14.3%Spironolactone100%Part D<11 patients+ 1 more class in this area
Blood & clotting
8.8%Solutions for parenteral nutrition8.8%Peg 3350-Electrolyte100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- Role of SUN1 in MASLD and metabolic disease
University of Michigan at Ann Arbor
FY2025$117,000R03DK137052 - Nuclear lamins and the hepatocyte nuclear envelope in nonalcoholic fatty liver disease
University of Michigan at Ann Arbor
FY2024$167,400K08DK120948 - Role of SUN1 in MASLD and metabolic disease
University of Michigan at Ann Arbor
FY2024$117,000R03DK137052
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”